Cholecalciferol Levels Research Articles

A further understanding of changes of wheat bran functionality induced by different types of probiotics fermentation: From molecules to regulation mechanism

Wheat bran (WB) was solid-state fermented by either Lacticaseibacillus rhamnosus (LGG), Levilactobacillus brevis (LB) or Lactiplantibacillus plantarum (LP), respectively, and then their corresponding physicochemical and metabolic characteristics were investigated. Current study revealed fermentation of either Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum quickly generated lactic acid, but not for Levilactobacillus brevis. Importantly, all LAB fermentation promoted total phenolic acids contents, fermentation of LB-WB led to the greatest total phenolic content, followed by LGG-WB, with the least for LP-WB. Moreover, LGG fermentation significantly increased levels of oleic acid, stearic acid and phosphoenolpyruvic acid on carbon metabolism and fatty acid biosynthesis, while LB fermentation mainly increased levels of L-phenylalanine, cholecalciferol, D-gluconic acid and D-glucarate with the influence on the entire metabolic pathway. In contrast, LP fermentation significantly decreased levels of alpha-ketoglutaric acid, cis-aconitic acid on the citrate cycle (TCA cycle). This study revealed their corresponding metabolic characteristics, which might highlight potentially individual nutritional aspects.

Exploring Vitamin D Deficiency and IGF Axis Dynamics in Colorectal Adenomas.

(1) Colorectal cancer is a major cause of cancer-related death, with colorectal adenomas (CRAs) serving as precursors. Identifying risk factors such as vitamin D deficiency and the insulin-like growth factor (IGF) axis is crucial for prevention. (2) This case-control study included 85 participants (53 CRA patients and 32 controls) who underwent colonoscopy. We measured serum vitamin D3 (cholecalciferol), calcidiol (vitamin D metabolite), calcitriol (active vitamin D metabolite), insulin-like growth factor-1 (IGF-1), and insulin-like growth factor binding protein-3 (IGFBP-3) to explore their associations with CRA risk. (3) Results: We found that lower cholecalciferol levels were a significant risk factor for CRA (OR = 4.63, p = 0.004). Although no significant differences in calcidiol and calcitriol levels were observed between CRA patients and controls, calcidiol deficiency was common in the study population. IGF-1 levels inversely correlated with age, calcitriol, and IGFBP-3 in CRA patients. (4) This study highlights the potential of lower cholecalciferol levels to detect patients at risk of CRA when calcidiol values cannot, suggesting the importance of evaluating different vitamin D metabolites in cancer prevention research. Our findings underscore the need to further investigate the interactions between calcitriol, the active form of vitamin D, and the IGF axis in colorectal cancer development.

#2823 High doses and levels of cholecalciferol for secondary hyperparathyroidism in hemodialysis patients

Abstract Background and Aims Vitamin D is crucial for musculoskeletal and general health. Low levels are associated with an increased risk of death and morbidity, including cancer, cardiovascular, autoimmune diseases and infections. In hemodialysis (HD) patients vitamin D deficiency plays additionally an important role in the pathogenesis of Chronic Kidney Disease–Mineral And Bone Disorder (CKD-MBD), including the development of secondary hyperparathyroidism (SHP). Determination of 25(OH)D levels in CKD patients and the administration of cholecalciferol according to the guidelines for the general population is recommended. The literature data show that therapy even with high doses of cholecalciferol appear to be safe and sufficient to increase 25(OH)D level > 30 ng/ml in HD patients. However, the prevailing opinion is that PTH lowering with cholecalciferol in CKD is unproven and clinically insignificant. The aim of the study was to evaluate the efficacy (including PTH concentration) and safety of increasing vitamin D levels from the recommended 30 ng/mL to >75 ng/mL in HD patients treated with high doses of cholecalciferol. Method 22 HD patients (16 M, 6 F)), with an average age of 72.5 ± 13.03 years and 25(OH)D concentration 30–50 ng/mL were administered cholecalciferol at a therapeutic dose of 70,000 IU/week (20,000 IU + 20,000 IU + 30,000 IU, immediately after each dialysis session) to reach the target serum 25(OH)D level > 75 ng/mL, but not longer than for 24 weeks. The baseline data on calcium, phosphate, 1,84 PTH, 25(OH)D and 1,25(OH)2D serum levels were compared with the data when 25(OH)D > 75 ng/mL was achieved or when the highest 25(OH)D levels were noted. Results A significant decrease in 1,84 PTH levels was observed during the study (542.36 ± 420.87 vs 230.99 ± 386.22 pg/mL; p < 0.005). No significant effect on calcium (8.91 ± 0.57 vs 9.03 ± 0.63 mg/dL; p = 0.23) and phosphate (4.6 ± 1.06 vs 4.81 ± 1.06 mg/dL; p = 0.93) concentrations was shown. There was also significant increase in 25(OH)D and 1,25(OH)2D levels (35.52 ± 8.26 vs 79.83 ± 21.38 ng/mL; p < 0.005, and 13.38 ± 7.26 vs 25.56 ± 12.80 pg/mL; p < 0.005, respectively). In the range of 25(OH)D levels 30-50 ng/mL 25(OH)D correlated positively with 1,25(OH)2D levels, r = 0.305. When 25(OH)D levels exceeded 50 ng/mL, there was negative correlation with 1,25(OH)2D levels (r = –0 .177 for 25(OH)D 50-75 ng/mL, and r = –0.262 for 25(OH)D >75 ng/mL). Conclusion Our study showed that the administration of high therapeutic doses of cholecalciferol to achieve 25(OH)D levels >75 ng/mL was safe, without the risk of hypercalcemia and hyperphosphatemia. Raising of 25(OH)D levels to the upper limit of the laboratory norm resulted in significant decrease in PTH levels. Cholecalciferol may be useful in the treatment of SHP in HD patients, but higher 25(OH)D levels seem to be crucial.

The association between serum cholecalciferol level and lipid profile in patients with latent autoimmune diabetes in adults

The association between serum cholecalciferol level and lipid profile in patients with latent autoimmune diabetes in adults

The dependence of anxiety and depression indicators on serum cholecalciferol level in patients with latent autoimmune diabetes in adults

The dependence of anxiety and depression indicators on serum cholecalciferol level in patients with latent autoimmune diabetes in adults

Optimal dual calcium and cholecalciderol dosages for osteoporotic fracture risk patients

Background: Vitamin D is crucial for musculoskeletal health, promoting calcium absorption, osteoid tissue mineralization, and muscle function. Insufficient levels can lead to bone dystrophy, muscle weakness, and osteoporotic fractures. Aims: This research investigates the correlation between bone mineral density and osteoporotic fracture risk, including positive and negative influences, and aims to determine the optimal vitamin D level. Methods: This retrospective observational study examined 206 Jordanian rehabilitation and rheumatology clinic patients from September to November 2021. The participants were post-menopausal women and men over 60. The Age-adjusted Charlson Co-Morbidity Index and Functionality Grade system was used to assess participants' co-morbidity burden and functionality. DEXA scans assessed participants' proximal femoral hip and anteroposterior spine. Participants were divided into two Vit D groups: those below 30 ng/ml and those above 30. Results were compared using a Chi Square test. The study examined correlations, total variations, and Vit D prediction quality using logistic regression analyses. SPSS 23.0 was used for statistical analysis with a 5% significance level. Results: A binary logistic regression model was employed to simulate the correlation between the vitamin D levels of patients and their bone mineral density. The model indicated a 61.39% likelihood of having a fH_BMD (femoral head bone mineral density) equal to or greater than 0.755 g/cm2 when the vitamin D level is at its optimal value of 27.25 ng/ml. The model indicated a 27.25% likelihood of a fHOPF risk-free tool with a value of ≥3% when the optimal vitamin D level is 27.25 ng/ml. The model indicated a 17.74% likelihood of experiencing a significant osteoporotic fracture within the next 10 years. Conclusion: The findings of our study demonstrated a direct correlation between elevated levels of vitamin D and improved bone mineral quality indices that were examined. The serum 25-OH Cholecalciferol levels are more likely to have a beneficial effect on bone health status.

EFFECT OF CHOLECALCIFEROL (VITAMIN D3) LEVELS ON VARIOUS TIMES AND DURATIONS OF EXPOSURE TO ULTRAVIOLET LIGHT (SUN EXSPOSURES)

Sunbathing triggers the vitamin D production, which functions to increase the immune system. Vitamin D is very beneficial for the health of the body, exposure to sunlight in sufficient time the body will get adequate vitamin D. The purpose of this study is to explain the level of vitamin D3 levels that are often found to occur due to exposure to ultraviolet rays of the sun (Sun Exposures). This research method is an experimental study with a completely randomized design (CRD). The research design used was a randomized post test only control group design. Data were analyzed using the Kruskal Wallis test with statistical test results obtained levels of Cholecalciferol (Vitamin D3) with p value = 0.675 (> 0.05) meaning there was no difference in each treatment group.

The vitamin- D quantity versus bone quality: A logistic based regression modeling in Jordanian cohort who at higher risk of osteoporotic fracture

Background: Several studies validated the positive impacts of Cholecalciferol derivatives; including dietary and non-dietary sources, on the bone architectural contents and the overall skeleton densities. We primarily aimed in this study to explore the optimal thresholds for the studied patients’ 25-OH Cholecalciferol levels that are correlated with the higher probabilities for having lumbar bone mineral density (LBMD) exceeding 0.835 g per cm2 and femoral hip bone mineral density (fH_BMD) exceeding 0.755 g per cm2. Methods: An observational retrospective study was conducted for patients, who are at risk of osteoporotic fracture, Firstly, a Binary Logistic Regression analysis was separately conducted for the investigated patients’ vitamin D levels against the patients’ fH_BMD ≥0.755 (Positive state) vs <0.755 (Negative state) and against the patients’ LBMD≥ 0.835 (Positive state) vs <0.835 (Negative state). Both the Receiver Operating Characteristic and the Sensitivity analyses were thereafter be conducted and the performances indices were explored. Results: Our constructed BLgR models, that logistically integrated the binary correlation between the investigated patients’ Vit D levels and their femoral hip or lumbar bone mineral densities, respectively, were constructed as [= e (--1.455+0.109× Vit D) /1+ e (--1.455+0.109× Vit D)] or [= e (--22.127+0.829× Vit D) /1+ e (--22.127+0.829× Vit D)], respectively. Conclusion: The optimal Vitamin D levels for our investigated Jordanian cohort to have a higher probability of lumber and femoral hip bone mineral; densities were identified at 27.05 ng/ml and 27.25 ng/ml, respectively.

Associations of Dietary Intake and Nutrient Status with Micronutrient and Lipid Composition in Breast Milk of Donor Women.

The influence of the diet and nutritional status of milk donors on the nutritional composition of donor human milk (DHM) is unknown. The present study aimed to determine the nutritional profile of DHM and the associations between donors' dietary intake and nutritional status and the micronutrient and lipid composition in DHM. For this purpose, 113 donors completed a food frequency questionnaire, provided a five-day weighed dietary record, and collected milk for five consecutive days. Nutrient determinations in donors' erythrocytes, plasma, urine, and milk were performed. Multiple linear regressions were conducted for the evaluation of the associations. We highlight the following results: DHM docosahexaenoic acid (DHA) was positively associated with donors' plasma DHA content and donors' DHA intake (R2 0.45, p < 0.001). For every 1 g/day DHA intake, an increase of 0.38% in DHA content and 0.78% in total omega-3 content was observed in DHM (R2 0.29, p < 0.001). DHM saturated fatty acids were positively associated with erythrocyte dimethyl acetals, plasma stearic acid, trans fatty acids intake, and breastfeeding duration and negatively associated with erythrocyte margaroleic acid (R2 0.34, p < 0.01). DHM cholecalciferol was associated with plasma cholecalciferol levels and dairy intake (R2 0.57, p < 0.01). Other weaker associations were found for free thiamin, free riboflavin, pyridoxal, dehydroascorbic acid, and the lipid profile in DHM. In conclusion, the diet and nutritional status of donors influence the fatty acid profile and micronutrient content of DHM.

The role of cholecalciferol deficiency in the development of latent autoimmune diabetes in adults

Background. Recently, a lot of information has appeared on the role of cholecalciferol deficiency in the development of the mechanisms of classical types of diabetes mellitus (DM) and its complications. However, there are currently almost no data regarding latent autoimmune diabetes in adults (LADA). The purpose of this study was to determine the effect of vitamin D deficiency on the compensation of carbohydrate metabolism in LADA. Materials and methods. The study included 56 patients with DM: 34 with LADA and 22 with classical type 1 DM (DM1), as well as 20 practically healthy individuals of the control group. According to the main phenotypes, patients with LADA were divided into 2 groups: LADA1 and LADA2. Cholecalciferol status was determined by the immunochemiluminescence method. Results. The fasting blood glucose level in LADA and DM1 group was significantly higher than in the controls, by 63.9 and 91.1 % (p &lt; 0.001), respectively, and was also 16.6 % higher when comparing DM1/LADA groups (p &lt; 0.05). The level of HbA1c in 66.1 % of patients of the experimental groups was more than 7 %, which indicates insufficient compensation of the disease. The content of vitamin D was significantly lower in the experimental groups compared to the controls; when comparing LADA/DM1 — by 43.7 % lower in case of classical DM1 (p &lt; 0.05). Compensation of carbohydrate metabolism is worse in patients with LADA1 than in LADA2, and the lowest level of vitamin D was recorded in LADA1. According to the linear regression analysis of correlations in patients with LADA, negative correlations of medium strength were recorded between the level of cholecalciferol and fasting blood glucose (r = 0.487; p &lt; 0.05), HbA1c (r = –0.593; p &lt; 0.05); positive — between cholecalciferol and C-peptide (r = 0.412; p &lt; 0.05). Conclusions. In patients with autoimmune diabetes, there is an insufficient supply of cholecalciferol. Low cholecalciferol content is observed in both groups of patients with LADA regardless of the disease phenotype and is associated with worse compensation of DM.

#4787 VITAMIN D AND PARATHYROID HORMONE PREDICT INCIDENT MAJOR ADVERSE CARDIAC EVENTS IN PATIENTS STARTING HAEMODIALYSIS: A REAL-WORLD ANALYSIS

Abstract Background and Aims Despite its advantages, haemodialysis (HD) is associated with increased cardiovascular mortality and morbidity, with some studies reporting 48% higher mortality, within 2 years of starting treatment. HD patients are known to suffer from vitamin D deficiency which has been linked to excess CV mortality and morbidity. We aimed to investigate the prognostic significance of vitamin D in predicting incident Major Adverse Cardiovascular Events (MACE) within 5 years of commencing HD. Method A retrospective cohort study was performed using electronic medical records from a global federated research network from the US (TriNetX). The TriNetX network was searched on 31st January 2023. The cohorts commenced HD post-diagnosis of End-Stage Kidney Disease. Data censoring for MACE was invoked prior to the index event of HD. Vitamin D (25-hydroxyvitamin D and 1,25 dihydroxy Vitamin D) concentrations were the first reported result within 3 months of starting HD. Cohorts were grouped according to biomarker-specific thresholds and 1:1 propensity-score matched for age, gender, and co-morbidities (hypertension, diabetes mellitus and smoking status). Logistical regression produced odds ratios with 95% CI for 5-year MACE. MACE was defined, a priori, as a composite of ischaemic heart disease, angina pectoris, acute myocardial infarction, heart failure, AF, stroke, and all-cause mortality. All statistical analysis was performed on the TriNetX online platform. Results The results are shown below. There was no association between outcome and PTH at 55 pg/ml threshold. Only results that reached statistical significance (p&amp;lt;0.05) are shown. Patients with a 25-OH Vitamin D concentration &amp;lt;24 ng/ml or 1,25-diOH Vitamin D at &amp;lt;35 pg/ml had significantly more events, as shown below. Conclusion Circulating plasma levels of cholecalciferol and calcitriol are predictive of CV outcomes in patients commencing HD; however, the risk profile is different between low levels of active and inactive vitamin D. As the incident HD population are at increased risk of CV mortality and morbidity, cholecalciferol and calcitriol should be included in assessing overall risk.

Cholecalciferol Supplementation Induced Up-Regulation of SARAF Gene and Down-Regulated miR-155-5p Expression in Slovenian Patients with Multiple Sclerosis.

Multiple sclerosis is a common immune-mediated inflammatory and demyelinating disease. Lower cholecalciferol levels are an established environmental risk factor in multiple sclerosis. Although cholecalciferol supplementation in multiple sclerosis is widely accepted, optimal serum levels are still debated. Moreover, how cholecalciferol affects pathogenic disease mechanisms is still unclear. In the present study, we enrolled 65 relapsing-remitting multiple sclerosis patients who were double-blindly divided into two groups with low and high cholecalciferol supplementation, respectively. In addition to clinical and environmental parameters, we obtained peripheral blood mononuclear cells to analyze DNA, RNA, and miRNA molecules. Importantly, we investigated miRNA-155-5p, a previously published pro-inflammatory miRNA in multiple sclerosis known to be correlated to cholecalciferol levels. Our results show a decrease in miR-155-5p expression after cholecalciferol supplementation in both dosage groups, consistent with previous observations. Subsequent genotyping, gene expression, and eQTL analyses reveal correlations between miR-155-5p and the SARAF gene, which plays a role in the regulation of calcium release-activated channels. As such, the present study is the first to explore and suggest that the SARAF miR-155-5p axis hypothesis might be another mechanism by which cholecalciferol supplementation might decrease miR-155 expression. This association highlights the importance of cholecalciferol supplementation in multiple sclerosis and encourages further investigation and functional cell studies.

Correlates of Myopathy in Diabetic Patients Taking Statins.

Diabetes is one of the most common chronic ailments; its incidence has reached epidemic proportions in the 21st century. Diabetes significantly increases micro and macrovascular complications, which are effectively managed with statins. Therefore, statins' pharmacokinetics, pharmacodynamics, and pharmacogenetics have been extensively studied. Although statins act as a keystone in preventing cardiovascular complications, at the same time, they pose a threat to the quality of life of diabetics due to the resulting muscular side effects. This article summarizes the prevalence, clinical manifestations, pathophysiology, and risk factors of statin-induced myopathy in diabetic patients. Among the diverse predisposing risk factors, the primary variables identified for causing myopathy in diabetic patients include age, gender, ethnicity, duration and severity of illness, comorbid conditions, level of physical activity, alcohol use, cholecalciferol (vitamin D3) levels, type and dose of statins, and anti-diabetic drugs or other drugs used concomitantly. In addition, cardiovascular risk quotients also potentially impact diabetic patients making them more vulnerable to developing myopathy from statins. Therefore, this study highlights the importance of managing statin-associated myopathic side effects by providing consensus guidelines on diagnostic, monitoring, and treatment strategies. We also discussed statins' prognostic value in reducing cardiovascular events in diabetic individuals.

Total Sialic Acid, Antioxidant Enzyme Activities, Trace Elements, and Vitamin Status Before and After Surgery in Women with Uterine Myoma and Endometrial Cancer.

The objective of present study was to examine endometrial tissue Be, As, Cr, Mo, Sr, Ti, Tl, Cu, Co, Se, Zn, Mn, Fe, Cd, Pb, Mg, P, erythrocytes CAT, SOD, GSH-Px, GSH, MDA, serum retinol, cholecalciferol, phylloquinone, TSA, LSA, TOS, and TAS status and to evaluate the relationships between the variables. The study had 110 participants; of these, 50 were women with uterine myoma (UM), 10 were women with endometrial cancer (EC), and 50 were healthy female subjects. In the study, vitamin analyses by HPLC and element analyses were determined using ICP-OES method. It was observed that EC group was significantly lower than healthy group in terms of levels of cholecalciferol (p < 0.05), phylloquinone (p < 0.01), GSH (p < 0.05), Fe (p < 0.05), and had a significant rise in Mg/Fe (p < 0.01) and Zn/Fe (p < 0.05) in preoperative period. UM group had significantly lower retinol (p < 0.05), phylloquinone (p < 0.001), GSH-Px (p < 0.01), GSH (p < 0.01), Cr (p < 0.01), Cu (p < 0.05), Mg (p < 0.01), and Zn (p < 0.01) levels than control group in preoperative period and significantly higher levels of MDA (p < 0.01), TSA (p < 0.01), and LSA (p < 0.01) than control group. It was found that significant associations were observed between Cu-CA 15-3 (r = 0.558, p = 0.016), Mn-CA 15-3 (r = 0.511, p = 0.030), P-CA 15-3(r = - 0.502, p = 0.034) and with UM, also between GSH-CA-125 (r = - 0.825, p = 0.022) and with EC group. The results of correlation analysis observed that concentrations of Cu, Mn, P, and GSH together with CA 15-3 and CA-125 levels might be important for monitoring patients with UM and EC before surgery.

Vitamin D Levels and Microvascular Complications in Type 2 Diabetes Mellitus Patients: A Study from North Keral

Introduction: Vitamin D plays an important role in glucose metabolism. Several pleiotropic effects of Vitamin D have been studied like regulation of cell proliferation, suppression of cell mediated immunity, Glial cell line-derived neurotrophic factor, stimulation of nerve growth factor, suppression of Renin-angiotensin-aldosterone system (RAAS), reduction of albuminuria, immunomodulatory effects, and anti-inflammatory effects.(1)Thus, vitamin D is implicated in the pathogenesis of retinopathy, neuropathy and nephropathy.&#x0D; Materials and Methods: A Cross-sectional case-control study of 206 patients (&gt;30 years), who met the American Diabetes Association, 2011 criteria (2) for type 2 DM, was conducted. Subjects were evaluated for the presence of microvascular complications by clinical evaluation, urine examination, fundus examination, clinical neuropathy scoring, and various biochemical tests. 25-OH cholecalciferol levels were done and cut off level for vitamin D deficiency was 30 ng/ml. 72 Vitamin D sufficient and 134 Vitamin D deficient cases were studied.&#x0D; Results: A total of 134 T2DM cases with Vitamin D deficiency were studied. 72 age matched T2DM patients with sufficient Vitamin D levels served as controls. The mean age of cases under study was 47.58 ± 9.63 years compared to 51.24 ± 8.75 years of controls. 61.2% were females, whereas 38.8% were males in the case group while in the control group, 69.4% were males, and 30.5% were females. The mean duration of diabetes in the cases studied was 57.08 ± 18.13 months. It was 52.69 ± 17.98 months in the Vitamin D sufficient controls. Significant statistical associations were established using Chi square test between Vitamin D status and development of microvascular complications like Diabetic nephropathy, retinopathy and neuropathy in Type 2 Diabetes Mellitus at p &lt; 0.05.&#x0D; Conclusion and Implication: Vitamin D is an important factor in modifying the risk of Type 2 DM and its microvascular complications, especially Diabetic retinopathy, neuropathy and nephropathy. Administration of vitamin D supplements may prove to be a beneficial adjuvant therapy in mitigating microvascular complications. Frequent Monitoring of Vitamin D status can decrease the burden of co-morbidities in T2DM and thus can decrease the mortality rate associated with T2DM. However; the exact role of vitamin D in these processes requires further investigations.&#x0D; Keywords:&#x0D; Diabetes, Nephropathy, Neuropathy, Retinopathy, Vitamin D

The Impact of Cholecaciferol Supplementation on Bone Mineral Density in Long-Term Kidney Transplant Recipients

Although reduced bone mineral density (BMD) is associated with a higher risk of fractures, morbidity, and mortality in kidney transplant patients (KTRs), there is no consensus on optimal treatment for the alterations of BMD in this population. This study aims at assessing the effect of cholecalciferol supplementation on BMD over a follow-up period of 2 years in a cohort of long-term KTRs. Patients with age ≥ 18 years were included and divided into two subgroups based on treatment with bisphosphonate and/or calcimimetics and/or active vitamin D sterols (KTRs-treated) or never treated with the above medications (KTRs-free). BMD was evaluated at lumbar vertebral bodies (LV) and right femoral neck (FN) with standard DEXA at the beginning and end of the study. According to World Health Organization (WHO) criteria, results were expressed as T-score and Z-score. Osteoporosis and osteopenia were defined as T score ≤ -2.5 SD and T score < -1 and >-2.5 SD, respectively. Cholecalciferol was supplemented at a dose of 25,000 IU/week over 12 weeks followed by 1500 IU/day. KTRs-free (n. 69) and KTRs-treated (n. 49) consecutive outpatients entered the study. KTRs-free were younger (p < 0.05), with a lower prevalence of diabetes (p < 0.05) and of osteopenia at FN (46.3 % vs. 61.2 %) compared to KTRs-treated. At the entry none of the study subjects had a sufficient level of cholecalciferol; Z-score and T-score at LV and FN were not different between groups. At the end of the study period, serum cholecalciferol concentration was significantly increased in both groups (p < 0.001); the KTRs-free group presented an improvement in both T-score and Z-score at LV (p < 0.05) as well as a lower prevalence of osteoporotic cases (21.7% vs. 15.9%); in contrast, no changes were recorded in KTR-treated individuals. In conclusion, supplementation with cholecalciferol ameliorated Z-score and T-score at LV in long-term KTRs who had been never treated with active or inactive vitamin D sterols, bisphosphonates, and calcimimetics. Future endeavours are needed to confirm these preliminary findings.

Assessing Adequacy of Cholecalciferol Supplementation in Chicks Using Plasma Cholecalciferol Metabolite Concentrations as an Indicator

Cholecalciferol (vitamin D) deficiency rickets remains an occasional problem in poultry. Diagnosis currently relies on analysis of feed and histopathological examination of bone. These experiments were designed to provide data that might allow diagnosis of cholecalciferol deficiency on the basis of plasma concentrations of 25-hydroxycholecalciferol, a circulating metabolite of cholecalciferol. Day-old broiler chicks were fed corn-soybean meal or purified ingredient cholecalciferol-deficient diets supplemented with 0, 5, 10, 15, 20, 25, 37.5 or 75 µg cholecalciferol/kg diet. Plasma and bone samples were collected 21 d later. Chicks fed the unsupplemented purified ingredient diet became truly deficient, having no detectable plasma concentrations of the cholecalciferol metabolites 25-hydroxycholecalciferol, 1,25-dihydroxycholecalciferol, or 24,25-dihydroxycholecalciferol. Chicks fed the corn-soybean meal diet without supplementation had low but detectable concentrations of both 25-hydroxycholecalciferol and 1,25-dihydroxycholecalciferol in plasma. Body weight, bone calcium and bone phosphorus concentrations of chicks fed the corn-soybean meal diet suggest that the cholecalciferol requirement of broiler chicks is at least 10 µg/kg diet. At this dietary level of cholecalciferol, plasma 25-dihydroxycholecalciferol concentration was 12.5 nmol/L. One hundred percent of the theoretical maximal response in body weight and bone calcium content was seen at 20 µg cholecalciferol/kg diet, which increased plasma 25-hydroxycholecalciferol concentration to 25 nmol/L in the chicks fed the corn-soybean meal diet. These data provide a nomogram of plasma 25-dihydroxycholecaiciferol concentration that can be expected from including different concentrations of cholecalciferol in the diet, and also offer a means of diagnosing cholecalciferol deficiency in field cases of rickets.

The Dietary Requirement of Juvenile Grass Shrimp (Penaeus monodon) for Vitamin D ,

Two 8-wk experiments were conducted to determine the adequate level of dietary vitamin D for juvenile grass shrimp (Penaeus monodon). In Experiment 1, purified diets with six levels (0, 0.1, 0.5, 2.5, 12.5 and 62.5 mg/kg diet) of supplemental ergocalciferol and cholecalciferol were fed to P. monodon (mean weight 0.19 +/- 0.02 g). In Experiment 2, we used 0, 0.05, 0.1, 0.2, 0.3, 0.6 and 1.0 mg/kg of supplemental cholecalciferol in basal diet fed to the shrimp (mean weight 0.25 +/- 0.03 g). In both experiments, shrimp fed vitamin D-deficient diets grew poorly. In Experiment 1, poorer growth performance was observed in shrimp fed diets containing ergocalciferol compared with those fed the diets containing cholecalciferol. In Experiment 2, weight gain was highest in shrimp fed the diet supplemented with 0.2 mg cholecalciferol/kg diet, followed by the groups fed 0.1 mg/kg, then 0.3 mg/kg, 0.05 and 0.6 mg/kg, 1.0 mg/kg, and finally the unsupplemented control group. The differences among these groups were significant (P < 0.05). The feed efficiency ratio and alkaline phosphatase activity generally followed the same pattern as the weight gain. Analysis by brokenline regression of weight gain and alkaline phosphatase activity of the shrimp in Experiment 2 indicated that the adequate dietary cholecalciferol concentration for growing P. monodon is approximately 0.1 mg/kg.

Calcifediol is a safe and effective metabolite for raising vitamin D status and improving growth and feed conversion in rainbow trout

The vitamin D endocrine system is required for the transcriptional regulation of a myriad of vertebrate genes including those involved in bone health, growth, nutrient metabolism and immunity. The requirements of salmonids for vitamin D are amongst the highest for any aquaculture species. With nuances, the metabolism of the pre-vitamin cholecalciferol (D3) via calcifediol (25-OH-D3), required to produce the physiologically active hormone calcitriol (1,25-OH-D3) is conserved in fish. The composition of modern aquafeeds, growth in seawater and production challenges, such as disease, may result in the suboptimal biochemical activation of vitamin D hormone in fish.A 91-day experimental feeding trial was used to test the safety and efficacy of calcifediol for the supply of vitamin D to rainbow trout with an initial body weight of 57.6 g. A practical diet containing cholecalciferol within recommended levels (5240 IU) was supplemented with either 69.8, 687 or 6854 μg/kg calcifediol. The efficacy of calcifediol was determined by the assessment of zootechnical performance and the appearance of vitamin D metabolites in the blood. The safety of the dietary interventions was assessed from generic health indices, examination of gross pathologies, hematology, and blood chemistry.Test fish increased body weight at least 5.6-fold to 323.5 g over the experimental feeding period. The supplementation of 687 or 6854 μg/kg calcifediol resulted in significant improvements in growth rate and feed conversion (FCR). Whilst not detectable in control fish, calcifediol increased linearly according to dietary levels in the blood and to a lesser extent in the white muscle. The increases of calcifediol in the blood were accompanied by saturable increases of circulating active vitamin D. At the end of the 91-day feeding period, survival was 100%, no gross pathologies relating to the diets were observed, and health indices, hematology, and blood chemistry, including calcium and phosphorus, were not significantly altered.The supplementation of calcifediol to practical diets containing recommended levels of cholecalciferol improves zootechnical performance and ensures that maximal levels of active vitamin D are present in the blood to meet physiological demands. With a lack of significant effects on health indices, hematology, and blood chemistry, including calcium and phosphorus, the tested high doses of calcifediol are concluded to be safe for salmonids.

Prevalence of Hypovitaminosis D among Athletes and its Impact on Athletic Performance: A Scoping Review

Abstract Recent studies have documented the importance of Vitamin D in improving immunity, mental health, and quality of life in various diseased conditions. Vitamin D is a genetic modulator involved in protein synthesis, immune activity, and optimal mineralization of bone which are essential to performance and training. This scoping review aims to identify the lacunae in the literature regarding hypovitaminosis and its impact on athletic performance. The methodology prescribed by Arksey and O’Malley and the methodological advancement by Levac were followed. Electronic databases, such as PubMed, Embase, Ovid Emcare, ProQuest, and Google Scholar, were searched for original research published in English between 1981 and 2021. Two authors completed the independent screening of titles, abstracts, and full-text articles to identify studies that met the inclusion criteria. Data was extracted and collated in a table to synthesize the results. Forty studies measured the prevalence rate of hypovitaminosis among athletes, of which nine assessed its impact on athletic performance. Hypovitaminosis D is prevalent among the athletic population, and factors such as race, training environment, location, and season impact the serum levels of cholecalciferol. The impact of hypovitaminosis D on athletic performance is inconclusive, with research showing divided results.